Doxofylline


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Reversible airways obstruction; COPD 400 mg bid-tid.
Dosage Details
Oral
COPD (chronic obstructive pulmonary disease), Reversible airways obstruction
Adult: 400 mg bid-tid. Max: 1,200 mg daily.
Child: <12 years 6-9 mg/kg bid; >12 years Same as adult dose.
Elderly: 200 mg bid-tid.
Contraindications
Acute MI, hypotension. Lactation.
Special Precautions
Patients with cardiac disease (e.g. cardiac arrhythmias, angina pectoris, CHF, acute myocardial injury, hypertension), peptic ulcer, hyperthyroidism, hypoxemia, chronic cor pulmonale, convulsive disorder. Hepatic and renal impairment. Children and elderly. Pregnancy.
Adverse Reactions
Cardiac disorders: Tachycardia, palpitation, extrasystole.
Metabolism and nutrition disorders: Hyperglycaemia.
Gastrointestinal disorders: Nausea, vomiting, abdominal pain, epigastric pain.
General disorders and administration site disorders: Irritability.
Nervous system disorders: Headache, nervousness, dizziness.
Psychiatric disorders: Insomnia, nervousness.
Renal and urinary disorders: Albuminuria.
Overdosage
Symptoms: Nausea, vomiting, gastroinstestinal bleeding, metabolic acidosis, hypokalaemia, hypotension, cardiac arrythmias, and seizures. Management: Symptomatic and supportive treatment. May induce emesis or perform gastric lavage followed by administration of activated charcoal and cathartic. Establish adequate airway. IV diazepam and/or phenobarbital may be given in cases of seizure.
Drug Interactions
Decreased xanthine clearance with cimetidine, allopurinol, propranolol, antibiotics (e.g. erythromycin, lincomycin, ciprofloxacin) and anti-flu vaccine. Increased xanthine clearance with anticonvulsants (e.g. phenytoin). May potentiate hypokalaemia with β2- agonist.
Action
Description: Doxophylline is a methylxanthine derivative that possesses potent bronchodilator activity by inhibiting phosphodiesterase enzymes followed by an increase in cyclic-3’, 5’ adenosine monophosphate (cAMP) resulting in smooth muscle relaxation.
Pharmacokinetics:
Absorption: Absolute bioavailability: Approx 62.6%. Time to peak plasma concentration: 30-60 minutes.
Distribution: Volume of distribution: Approx 1 L/kg. Plasma protein binding: Approx 48%.
Excretion: Via urine (< 4% as unchanged drug). Elimination half-lie: >6 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Doxofylline, CID=50942, https://pubchem.ncbi.nlm.nih.gov/compound/Doxofylline (accessed on Jan. 21, 2020)

Storage
Store below 30°C.
ATC Classification
R03DA11 - doxofylline ; Belongs to the class of xanthines. Used in the systemic treatment of obstructive airway diseases.
References
Cazzola M, Calzetta L, Rogliani P et al. Impact of Doxofylline in COPD: A Pairwise Meta-analysis. Pulmonary Pharmacology & Therapeutics. 51:1-9. https://doi.org/10.1016/j.pupt.2018.04.010. Accessed 30/01/2019

Anon. Doxofylline. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 30/01/2019.

Buckingham R (ed). Doxofylline. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com . Accessed 30/01/2019.

Dilatair (Ajanta Pharma Phil). MIMS Philippines. http://www.mims.com/philippines. Accessed 30/01/2019.

Doxofix (UNILAB, Inc). MIMS Philippines. http://www.mims.com/philippines. Accessed 30/01/2019.

Doxopro (InnoGen Pharmaceuticals). MIMS Philippines. http://www.mims.com/philippines. Accessed 30/01/2019.

Maxivent (Ajanta Pharma Phil). MIMS Philippines. http://www.mims.com/philippines. Accessed 30/01/2019.

Xanthines. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com/. Accessed 30/01/2019.

Disclaimer: This information is independently developed by MIMS based on Doxofylline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in